MAP2K7 and appendix cancer: In this study, we tested the efficacy of dual MEK‐PI3K drug therapy against mucinous colon/appendix cancers since these tumors demonstrate unique phenotypic and genotypic features that are likely to be predictive of sensitivity to this combination therapy.